ESMO publishes updated guidelines on cancer care

Jul 08, 2010

The European Society for Medical Oncology (ESMO) just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients.

The ESMO Clinical (CPG) offer vital, evidence-based information including the incidence of the malignancy, diagnostic criteria, staging of disease and risk assessment, treatment plans and follow-up.

Formerly known as the ESMO Clinical Recommendations, the ESMO Clinical Practice Guidelines are intended to provide users with a set of requirements for the highest standard of care for cancer patients.

"The Clinical Practice Guidelines are central to ESMO's mission, which is to advance and cure through fostering and disseminating good science that leads to better medicine and determines best practice," said ESMO President Prof David Kerr.

A growing number of the new guidelines have been developed using large, multidisciplinary writing groups, ensuring optimal input from the oncology profession and a better geographic representation.

"ESMO is constantly striving to improve the care of cancer patients worldwide," said Prof Kerr. "By developing these new guidelines with the assistance of a wide range of clinicians we can help share the joint expertise of the world's best doctors from many disciplines."

The ESMO Clinical Practice Guidelines include guidelines for , colorectal cancer and non-small-cell lung cancer that have been expanded to include more treatment details and further discussion of the importance of multidisciplinary plans for particular patient settings.

Lung cancer is now dealt with in two distinct guidelines, one covering early and locally-advanced cancer, while the other focuses on metastatic disease.

One new guideline is focused specifically on cardiotoxicity, a potential side-effect of some chemotherapeutic agents.

Four further guidelines have been rewritten, drawing on the knowledge of the global oncology community. These include guidelines on soft tissue sarcoma and bone sarcoma, and a guideline on the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.

The guideline on the prevention of chemotherapy- and radiotherapy-induced nausea was developed as the result of the 3rd Perugia Consensus Conference organized by the Multinational Association of Supportive Care in Cancer (MASCC) and ESMO.

"ESMO is striving to further increase the value of its guidelines by introducing a more multidisciplinary approach in their development, not only through the use of physical meetings but also through the ESMO Professional Networking Community," said Prof Kerr.

Other guidelines have also been reviewed:

  • Pancreatic cancer: including more detail relating to treatment planning in all stages of the disease.
  • epatacellular cancer: including an expanded section in surgical and medical treatment, especially targeted therapy.
  • Multiple myeloma: revised according to new drug indications.
  • Gastrointestinal stromal tumors (GIST): revised with more treatment-orientated details.
  • Cancer, fertility and pregnancy: including more information on treatment, especially surgery and highlighting problems of breast, cervical and myeloma cancer in pregnancy as well as further details about delivery of chemotherapy, hormonal and targeted therapy, radiotherapy and supportive agents in pregnant women with cancer.
  • Endometrial cancer: including a new section of histology and further guidance on treatment options in these settings.
  • Management of febrile neutropenia: including more detail on treatment assessments and how to manage patients.
The new guidelines published in June represent the first stage of a process that will include for more than 55 different clinical situations, covering almost all tumor types as well as various other topics, including the therapeutic use of growth factors.

Explore further: AstraZeneca cancer drug, companion test approved

Provided by European Society for Medical Oncology

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Personalized treatment for early lung cancer

May 03, 2009

Cancer vaccines and targeted therapies are beginning to offer new treatment options following surgery for patients with early stages of lung cancer, experts said at the first European Multidisciplinary Conference in Thoracic ...

Investigational drug shows promise in ovarian cancer

Sep 15, 2008

An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical ...

Recommended for you

Putting the brakes on cancer

10 hours ago

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

Peanut component linked to cancer spread

11 hours ago

Scientists at the University of Liverpool have found that a component of peanuts could encourage the spread and survival of cancer cells in the body.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.